Summit Corporation plc
(‘Summit’ or ‘the Company’)

SUMMIT OUTLINES CLINICAL TRIAL PLANS FOR ITS DUCHENNE MUSCULAR DYSTROPHY PROGRAMME

- Clinical Trial Application expected to be submitted in Q1 2012
- Headline results from Phase I study anticipated in Q3 2012

Oxford, UK, 14 February 2012, Summit (AIM: SUMM), a UK drug discovery company, today outlines its clinical trial plans for SMT C1100, a potential first-in-class disease modifying drug for the treatment of the fatal rare disease Duchenne Muscular Dystrophy (‘DMD’).

DMD is a neuromuscular disease and is caused by the absence of dystrophin, a protein which is essential in maintaining the healthy function of muscles in the body. SMT C1100 is a small molecule that works by producing a naturally occurring protein called utrophin to substitute for the missing dystrophin. This is the only approach in development that continually makes new utrophin and has the potential to treat all DMD patients, regardless of their specific genetic mutation. A drug to treat DMD has the potential to generate annual sales in excess of $1 billion.

SMT C1100 has been extensively evaluated in non-clinical efficacy and safety studies and has demonstrated its ability to restore and maintain the function of muscles. A Phase I clinical trial in healthy volunteers will now be conducted by Summit. The trial will evaluate if the new formulation of SMT C1100 can provide consistent levels of the drug in the blood that non-clinical efficacy studies predicted would be required to confer therapeutic benefit in DMD patients, while also further assessing its safety. The new formulation will be appropriate for use by all DMD patients.

The manufacture and formulation of SMT C1100 is currently on-track and Summit expects to submit a clinical trial application (‘CTA’) to the Medicines and Healthcare products Regulatory Agency (‘MHRA’) in Q1 2012. If CTA approval is granted, the Phase I trial would commence with headline results from this study anticipated in Q3 2012. A successful outcome from the Phase I trial could lead to a Phase II study in DMD patients starting in H1 2013.

The Phase I clinical trial is completely funded by the $1.5 million agreement signed in December 2011 between Summit and the Muscular Dystrophy Association, Parent Project Muscular Dystrophy, Charley’s Fund, Cure Duchenne, the Foundation to Eradicate Duchenne and the Nash Avery Foundation.

Barry Price, PhD, Executive Chairman of Summit commented: “Summit is pleased to report that our plans to commence a new Phase I clinical trial for SMT C1100 are progressing well following the recent agreement signed with the DMD organisations. This clinical trial represents a key development milestone for the programme with a successful outcome having the potential to add considerable value to this asset, and bring an urgently needed treatment for this terrible disease a step closer.”

Valerie Cwik, M.D., MDA Interim President and Medical Director added: “We at MDA are excited about the continuing progress in the development of SMT C1100 as a therapy for DMD. MDA has supported utrophin upregulation as a therapeutic strategy for DMD for several years and is pleased to partner with Summit in the development of this promising drug.”

- END -
Notes to Editors

About DMD
Duchenne muscular dystrophy is a fatal genetic neuromuscular disorder that affects 1 in 3,500 boys with an estimated patient population of 50,000 in the developed world. The disease is caused by the lack of a gene required to make dystrophin, a protein which maintains the integrity and healthy function of muscles. One in three new cases is due to a spontaneous mutation where there is no familial history of the disease. The progressive muscle wasting begins in early childhood and typically leads to death in the twenties due to cardiac and respiratory failure. Currently there is no cure for the disease.

About Utrophin Upregulation
Utrophin is a naturally occurring protein that has a similar function to dystrophin. Utrophin is produced during foetal development but is switched off in adults. If its production could be switched back on, utrophin could act as a substitute for the missing dystrophin to maintain the healthy function of muscles. One method of turning utrophin production back on is through pharmacological means. Utrophin upregulation will be beneficial to all DMD patients regardless of their specific genetic mutation and is also expected to be complimentary to other therapeutic approaches in development.

About SMT C1100
Discovered and developed by scientists at Summit, SMT C1100 has demonstrated its potential as a disease modifying drug in non-clinical efficacy studies. SMT C1100 disengages normal utrophin control such that utrophin RNA and protein is made continually in muscle. It has received orphan drug designation in the US and Europe. In December 2011 Summit signed a $1.5 million agreement with a group of US-based DMD organisations to support the development of SMT C1100. The organisations involved are the Muscular Dystrophy Association (www.mda.org), Parent Project Muscular Dystrophy (www.ParentProjectMD.org) and a group of four independent Duchenne foundations spanning the US: Charley’s Fund (www.charleysfund.org), Cure Duchenne (www.cureduchenne.org), Foundation to Eradicate Duchenne (www.duchennemd.org) and Nash Avery Foundation (www.nashaveryfoundation.org).

About Summit
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin™ technology platform for the discovery of new medicines and a portfolio of drug programme assets. Seglin™ technology is using new chemistry to access biological drug targets that cannot be exploited by conventional drug discovery approaches and it is expected to have broad use in major disease areas. Summit’s programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.
Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com.

Forward Looking Statements
This document contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipates", "intends", "plans", "seeks", "believes", "estimates", "expects" and similar references to future periods, or by the inclusion of forecasts or projections. Forward-looking statements are based on the Company's current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. The Company cautions you therefore that you should not rely on any of these forward-looking statements as statements of historical fact or as guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements and regional, national, global political, economic, business, competitive, market and regulatory conditions.